HGH and Blood Pressure: Does Growth Hormone Raise BP?
Updated: 3 days ago
By HGHThailand Team
Growth hormone and blood pressure connect mainly at the extremes. Long-term growth hormone excess (acromegaly) is frequently accompanied by high blood pressure, and growth hormone deficiency is linked to higher cardiovascular risk. Whether treatment changes blood pressure numbers is studied, but the effects are modest, and blood-pressure problems always need a doctor.
Key points
Hypertension is one of the most common complications of acromegaly, the condition of prolonged growth hormone excess.
Growth hormone deficiency is associated with a cluster of cardiovascular risk factors, including blood pressure, body composition and lipid profile.
In adults with confirmed deficiency, studies of growth hormone treatment report small average changes in blood pressure alongside other cardiac measures, not a reliable way to control blood pressure.
Growth hormone is a prescription medicine approved for specific diagnosed conditions, not for lowering blood pressure.
Any blood-pressure concern should be assessed and managed by a qualified healthcare professional.
How can growth hormone affect blood pressure?
Growth hormone (GH, also called somatropin) is a peptide hormone made in the pituitary gland; our overview explains what human growth hormone is and how it circulates. It acts directly on tissues and indirectly through insulin-like growth factor 1 (IGF-1), mainly produced by the liver. Because it influences fluid balance, blood vessels and metabolism, it can plausibly touch the systems that set blood pressure.
A 2019 review of hypertension in acromegaly describes the likely mechanisms as a combination of factors: expansion of extracellular fluid volume, an increase in peripheral vascular resistance, and the development of sleep apnoea (Puglisi and Terzolo). Those are the physiological routes through which sustained growth hormone excess is thought to raise blood pressure. The same review notes that the picture is not fully understood, which is why it describes hypertension as a common but incompletely explained complication.
This is a mechanism-level explanation, not a treatment guide. It describes what happens when growth hormone levels are abnormal for a long time; it does not describe what any person should do about their own blood pressure.
What happens with too much growth hormone (acromegaly)?
Acromegaly is a rare condition in which the pituitary gland produces too much growth hormone over years, most often because of a benign tumour. It is the clearest clinical setting for HGH hypertension. In the 2019 review, hypertension was reported in a median of 33.6% of people with acromegaly, with figures across studies ranging from 11% to 54.7% (Puglisi and Terzolo).
That wide range reflects differences in how the studies were designed and how blood pressure was measured. The consistent message, however, is that high blood pressure is one of the most frequent complications of the condition, and it contributes to the higher cardiovascular risk seen in people who live with untreated acromegaly for a long time. The review stresses early detection and prompt treatment of the hypertension itself, guided by a clinician.
It is worth being precise here: acromegaly is a diagnosed medical condition, not a description of someone who has used growth hormone supplements. The blood-pressure findings come from patients with a confirmed hormonal disease and are reported in that clinical context.
What about growth hormone deficiency?
At the other end of the spectrum, the link between growth hormone deficiency and blood pressure forms part of the heart-HGH connection. Adults with growth hormone deficiency (GHD) also show a higher-than-expected burden of cardiovascular risk. A review in *Clinical Endocrinology* concluded that GHD is associated with several established risk factors, including body shape, lipid profile, insulin resistance, blood pressure, vessel-wall structure and haemostatic factors (McCallum and colleagues).
The relationship is bidirectional and still debated. The same review cautions that it is difficult to separate the effect of the deficiency itself from the underlying pituitary disorder and from the other hormone replacements a patient may receive. So "low growth hormone" is associated with cardiovascular risk markers, but association is not the same as proving that raising growth hormone levels fixes them.
One small physiological detail helps explain why fluid balance keeps coming up. A study in *PLOS ONE* measured extracellular water in adults with GHD and found it reduced compared with normal; after growth hormone replacement, extracellular water increased and blood pressure either fell or stayed the same in that cohort (Barbosa and colleagues). In other words, the fluid shifts that accompany treatment do not translate neatly into a predictable change in blood pressure.
Does growth hormone treatment change blood pressure?
Medical treatment for adults with confirmed GHD exists, and researchers have tried to measure its cardiovascular effects. An updated meta-analysis published in *Pituitary* pooled 11 controlled trials of growth hormone treatment in adults with GHD (Zhang and colleagues).
Across those trials, treatment was associated with a small average fall in diastolic blood pressure (a weighted mean difference of about 1.2 mmHg), together with improvements in some echocardiographic measures, such as ejection fraction, and a fall in NT-proBNP, a marker of cardiac strain. The same analysis found a modest increase in heart rate.
The authors framed these as improvements in "general vital signs and quality of life" in a treated deficiency population. The important caveats: the change in blood pressure was small, the studies were in people with a diagnosed deficiency receiving supervised medical care, and pooled averages hide wide individual variation. A drop of roughly 1 mmHg is far smaller than the effect expected from standard blood-pressure medication.
This matters for anyone reading "HGH lowers blood pressure" as a takeaway. The research signal is modest and specific to humans with a treated clinical deficiency, not a general effect in healthy adults.
Is growth hormone approved for blood pressure?
No. In the United States, somatropin products are prescription medicines approved for specific diagnosed conditions. The prescribing information for one widely used brand, Genotropin, lists several paediatric growth conditions, including growth hormone deficiency, Prader-Willi syndrome, small for gestational age, Turner syndrome and idiopathic short stature. In adults, the approved use is adult-onset or childhood-onset growth hormone deficiency (DailyMed, FDA-approved labelling).
High or low blood pressure is not among the approved uses, and the labelling lists fluid retention (swelling, joint pain, carpal tunnel symptoms, especially in adults) and headaches among the common adverse reactions of somatropin treatment. This means the medicine can itself be associated with fluid-related effects, another reason blood pressure in anyone using it should be monitored by a clinician.
Regulatory status differs by country, and this article does not make claims about any specific jurisdiction beyond the US labelling above. If you are unsure how a product is regulated where you live, that is a question for a doctor or pharmacist.
What this means if you are concerned about blood pressure
Growth hormone extremes (sustained excess or confirmed deficiency) are associated with cardiovascular and blood-pressure problems, but they are diagnosed and managed medically, not self-managed. Research on treatment shows small, mixed, population-level effects, not a reliable blood-pressure solution.
If you have high or low blood pressure, the right first step is a clinical assessment: proper measurement, review of your medicines and history, and a management plan from a qualified healthcare professional. If you are considering any hormone treatment, discuss it with a doctor who can run the appropriate tests and interpret them.
FAQ
Does HGH raise blood pressure?
Prolonged growth hormone excess (acromegaly) is commonly accompanied by high blood pressure: one 2019 review reported it in a median of 33.6% of cases. This reflects a diagnosed hormonal disease, not typical supplement use. Blood pressure in that setting is managed by clinicians.
Can HGH lower blood pressure?
In adults with confirmed growth hormone deficiency, a 2020 meta-analysis of 11 trials found a small average fall in diastolic blood pressure (about 1.2 mmHg) during supervised treatment. That is a modest research finding in a treated deficiency population, not a reason to use growth hormone for blood pressure.
Is growth hormone a blood-pressure medication?
No. Somatropin is a prescription medicine approved for specific diagnosed conditions such as growth hormone deficiency, and high blood pressure is not an approved use. Fluid retention is listed among its common adverse reactions.
What should I do if I have blood-pressure concerns?
Speak to a qualified healthcare professional for measurement and management. This article is general information and cannot replace an individual assessment.
Disclaimer
This article is for general information only and is not medical advice. It does not diagnose, treat, cure or prevent any condition, and it is not a substitute for consultation with a qualified healthcare professional. Blood-pressure concerns should be assessed by a doctor. Statements about research findings describe published studies and populations, not personal results.
Sources
Puglisi S, Terzolo M. "Hypertension and Acromegaly." *Endocrinology and Metabolism Clinics of North America* (Elsevier). 2019;48(4):779–793. PMID 31655776. https://pubmed.ncbi.nlm.nih.gov/31655776/
Zhang S, Li Z, Lv Y, et al. "Cardiovascular effects of growth hormone (GH) treatment on GH-deficient adults: a meta-analysis update." *Pituitary* (Springer). 2020;23(4):467–475. PMID 32166618. https://pubmed.ncbi.nlm.nih.gov/32166618/
McCallum RW, Petrie JR, Dominiczak AF, Connell JM. "Growth hormone deficiency and vascular risk." *Clinical Endocrinology* (Wiley). 2002;57(1):11–24. PMID 12100064. https://pubmed.ncbi.nlm.nih.gov/12100064/
Barbosa EJ, Glad CA, Nilsson AG, et al. "Extracellular water and blood pressure in adults with growth hormone (GH) deficiency: a genotype-phenotype association study." *PLOS ONE*. 2014;9(8):e105754. PMID 25157616. https://pubmed.ncbi.nlm.nih.gov/25157616/
Genotropin (somatropin): FDA-approved prescribing information. *DailyMed*, US National Library of Medicine. Accessed 2026-10-05. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ffebf88b-d257-4542-9808-74d9b7167765